NCT06717360CompletedPhase 3
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
A Multicenter, Randomized, Double-blinded, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients With Primary Hypercholesterolemia
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 158 (actual)
- First submitted
- 28 Nov 2024
- Start date
- 30 Sept 2024
- Primary completion date
- 10 Jul 2025
- Lead sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT06717360
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 158
- From 30 Sept 2024 to the primary completion date, 10 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- The subject not meet the specified LDL-C level
- Other exclusions applied
Who the study is looking for
- Adults aged 19-80
- Patients with primary hypercholesterolemia
- Those who voluntarily written consent to participate in this clinical trial
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AhnGook Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.